Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Gilead Sciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Gilead Sciences Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Gilead Sciences Inc, Medical Equipment, Deal Details 11
Partnerships 11
Kite Pharma Enters into Agreement with Vitruvian Networks 11
Debt Offering 12
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 12
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 14
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 16
Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 18
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 20
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 22
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 24
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 26
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 28
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 30
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 32
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 34
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 36
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 38
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 40
Acquisition 42
United Therapeutics May Sell Itself 42
Gilead Sciences Inc – Key Competitors 43
Gilead Sciences Inc – Key Employees 44
Gilead Sciences Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 49
Recent Developments 50
Financial Announcements 50
Oct 26, 2017: Gilead Sciences Announces Third Quarter 2017 Financial Results 50
Jul 26, 2017: Gilead Sciences Announces Second Quarter 2017 Financial Results 52
May 02, 2017: Gilead Sciences Announces First Quarter 2017 Financial Results 54
Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 56
Nov 01, 2016: Gilead Sciences Announces Third Quarter 2016 Financial Results 58
Jul 25, 2016: Gilead Sciences Announces Second Quarter 2016 Financial Results 60
Apr 28, 2016: Gilead Sciences Announces First Quarter 2016 Financial Results 62
Feb 02, 2016: Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results 64
Corporate Communications 67
Oct 17, 2017: Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics 67
Sep 27, 2017: Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire 68
Jan 03, 2017: Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head 69
Nov 16, 2016: Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations 70
Aug 23, 2016: Kelly A. Kramer Joins Gilead Sciences’ Board of Directors 71
May 24, 2016: Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy 72
Feb 01, 2016: Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources 73
Jan 29, 2016: Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director 74
Jan 29, 2016: AHF: Gilead Billionaire CEO John Martin Steps Down 75
Government and Public Interest 76
Aug 11, 2016: ATF Urges Treasury and IRS to Act Against Gilead Science’s Massive Offshore Tax Dodging 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
Gilead Sciences Inc, Medical Equipment, Key Facts, 2016 2
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Gilead Sciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Gilead Sciences Inc, Deals By Market, 2011 to YTD 2017 9
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Kite Pharma Enters into Agreement with Vitruvian Networks 11
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 12
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 14
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 16
Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 18
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 20
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 22
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 24
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 26
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 28
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 30
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 32
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 34
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 36
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 38
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 40
United Therapeutics May Sell Itself 42
Gilead Sciences Inc, Key Competitors 43
Gilead Sciences Inc, Key Employees 44
Gilead Sciences Inc, Other Locations 45
Gilead Sciences Inc, Subsidiaries 45
Gilead Sciences Inc, Joint Venture 49